Ekso Bionics Holdings, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 15 - Net Loss Per Share

Note 15 - Net Loss Per Share

3 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Earnings Per Share [Text Block]

15. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per common share:

	*Three Months Ended*
	*March 31,*
	*2025*			*2024*
Numerator:
Net loss applicable to common stockholders	$	(2,891	)	$	(3,429	)
Adjustment for deemed dividend ^(*)	$	(226	)	$	—
Adjusted net loss used for basic and diluted calculation	$	(3,117	)	$	(3,429	)

Denominator:
Weighted-average number of common shares, basic and diluted		25,393			17,419

Net loss per common share:
Basic and diluted	$	(0.12	)	$	(0.20	)

^(*) Deemed dividend represents the Company's incremental fair value of the Inducement Warrant over the gross proceeds received, which reduces income available to common stockholders used for the basic and diluted net loss per common share calculation. Refer to Note 11. Capitalization and Equity Structure – Warrants for additional information regarding the Inducement Warrant.

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive as of the end of each period presented:

	*Three Months Ended*
	*March 31,*
	*2025*		*2024*
Options to purchase common stock		181		197
Restricted stock units		836		1,133
Warrants for common stock		13,696		1,240
Shares held in abeyance		6,984		—
Total common stock equivalents		21,697		2,570